RSS feed

Publications (original articles or review articles) published in 2024 from OUS - Department of Cancer Genetics

46 publications found

Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, Kim D, Potdar S, Wolf M, Lotfi K, Aittokallio T, Wennerberg K, Porkka K, Mustjoki S (2024)
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia
Cell Rep Med, 5 (5), 101521
DOI 10.1016/j.xcrm.2024.101521, PubMed 38653245

Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352

Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720

Ankill J, Zhao Z, Tekpli X, Kure EH, Kristensen VN, Mathelier A, Fleischer T (2024)
Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation
PLoS Comput Biol, 20 (11), e1012565
DOI 10.1371/journal.pcbi.1012565, PubMed 39556603

Arner EN, Alzhanova D, Westcott JM, Hinz S, Tiron CE, Blø M, Mai A, Virtakoivu R, Phinney N, Nord S, Aguilera KY, Rizvi A, Toombs JE, Reese TC, Fey V, Micklem D, Gausdal G, Ivaska J, Lorens JB, Brekken RA (2024)
AXL-TBK1 driven AKT3 activation promotes metastasis
Sci Signal, 17 (867), eado6057
DOI 10.1126/scisignal.ado6057, PubMed 39689180

Bai B, Wise JF, Vodák D, Nakken S, Sharma A, Blaker YN, Brodtkorb M, Hilden V, Trøen G, Ren W, Lorenz S, Lawrence MS, Myklebost O, Kimby E, Pan-Hammarström Q, Steen CB, Meza-Zepeda LA, Beiske K, Smeland EB, Hovig E, Lingjærde OC, Holte H, Myklebust JH (2024)
Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma
Blood Cancer J, 14 (1), 147
DOI 10.1038/s41408-024-01124-5, PubMed 39191762

Brativnyk A, Ankill J, Helland Å, Fleischer T (2024)
Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma
Int J Cancer, 155 (2), 282-297
DOI 10.1002/ijc.34915, PubMed 38489486

Braadland PR, Farnes I, Kure EH, Yaqub S, McCann A, Ueland PM, Labori KJ, Hov JR (2024)
Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer
Front Oncol, 14, 1488749
DOI 10.3389/fonc.2024.1488749, PubMed 39759130

Bulanova D, Akimov Y, Senkowski W, Oikkonen J, Gall-Mas L, Timonen S, Elmadani M, Hynninen J, Hautaniemi S, Aittokallio T, Wennerberg K (2024)
A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells
Sci Adv, 10 (21), eadj1564
DOI 10.1126/sciadv.adj1564, PubMed 38781347

Chen L, Wang X, Xie N, Zhang Z, Xu X, Xue M, Yang Y, Liu L, Su L, Bjaanæs M, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Christiani DC, Chen F, Zhang R (2024)
A two-phase epigenome-wide four-way gene-smoking interaction study of overall survival for early-stage non-small cell lung cancer
Mol Oncol, 19 (1), 173-187
DOI 10.1002/1878-0261.13766, PubMed 39630602

Cun HT, Bernard L, Lande KT, Lawson BC, Nesbakken AJ, Davidson B, Lindemann K, Fellman B, Sørlie T, Soliman PT, Eriksson AGZ (2024)
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma
Gynecol Oncol, 189, 138-145
DOI 10.1016/j.ygyno.2024.07.677, PubMed 39126895

Davidson B, Teien Lande K, Nebdal D, Nesbakken AJ, Holth A, Lindemann K, Zahl Eriksson AG, Sørlie T (2024)
Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
Virchows Arch (in press)
DOI 10.1007/s00428-024-03912-7, PubMed 39235515

Demir MF, Lin YH, Costa Cruz PH, Tajima M, Honjo T, Müller E (2024)
Blocking S100A9-signaling is detrimental to the initiation of anti-tumor immunity
Front Immunol, 15, 1479502
DOI 10.3389/fimmu.2024.1479502, PubMed 39497822

Dyrbekk APH, Warsame AA, Suhrke P, Ludahl MO, Zecic N, Moe JO, Lund-Iversen M, Brustugun OT (2024)
Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer
Clin Exp Med, 24 (1), 10
DOI 10.1007/s10238-023-01273-0, PubMed 38240952

Edsjö A, Russnes HG, Lehtiö J, Tamborero D, Hovig E, Stenzinger A, Rosenquist R, PCM4EU consortium (2024)
High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond
J Intern Med, 295 (6), 785-803
DOI 10.1111/joim.13785, PubMed 38698538

Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD (2024)
Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
Front Immunol, 15, 1480183
DOI 10.3389/fimmu.2024.1480183, PubMed 39687621

Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N (2024)
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
ESMO Open, 9 (6), 103464
DOI 10.1016/j.esmoop.2024.103464, PubMed 38833971

Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN (2024)
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
Mol Oncol, 18 (8), 2042-2059
DOI 10.1002/1878-0261.13656, PubMed 38671580

Førde D, Kilvær T, Pedersen MI, Blix ES, Urbarova I, Paulsen EE, Rakaee M, Busund LR, Donnem T, Andersen S (2024)
High density of TCF1+ stem-like tumor-infiltrating lymphocytes is associated with favorable disease-specific survival in NSCLC
Front Immunol, 15, 1504220
DOI 10.3389/fimmu.2024.1504220, PubMed 39749327

Gullhaug A, Haakensen VD, De Ruysscher D, Simone CB, Hotca-Cho AE, Chhabra AM, Hellebust TP, Paulsen EE, Dimopoulos MP, Johansen S (2024)
Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes
J Med Imaging Radiat Sci, 55 (2), 221-231
DOI 10.1016/j.jmir.2024.02.004, PubMed 38429174

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjærde OC, Tveit KM, Spindler KG, Pallisgaard N, Kure EH (2024)
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
Clin Colorectal Cancer (in press)
DOI 10.1016/j.clcc.2024.11.004, PubMed 39743478

Hektoen HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, Brustugun OT, Andreassen BK (2024)
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study
Br J Cancer, 132 (1), 93-102
DOI 10.1038/s41416-024-02895-1, PubMed 39489879

Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
Eur J Cancer, 202, 113973
DOI 10.1016/j.ejca.2024.113973, PubMed 38447379

Ianevski A, Kushnir A, Nader K, Miihkinen M, Xhaard H, Aittokallio T, Tanoli Z (2024)
RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies
Brief Bioinform, 25 (4)
DOI 10.1093/bib/bbae328, PubMed 38980370

Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, Ruokoranta T, Kuusanmäki H, Ikonen N, Sergeev P, Vähä-Koskela M, Giri AK, Vähärautio A, Kontro M, Porkka K, Pitkänen E, Heckman CA, Wennerberg K, Aittokallio T (2024)
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones
Nat Commun, 15 (1), 8579
DOI 10.1038/s41467-024-52980-5, PubMed 39362905

Karttunen K, Patel D, Sahu B (2024)
Transposable elements as drivers of dedifferentiation: Connections between enhancers in embryonic stem cells, placenta, and cancer
Bioessays, 46 (10), e2400059
DOI 10.1002/bies.202400059, PubMed 39073128

Moragas N, Fernandez-Nogueira P, Recalde-Percaz L, Inman JL, López-Plana A, Bergholtz H, Noguera-Castells A, Del Burgo PJ, Chen X, Sorlie T, Gascón P, Bragado P, Bissell M, Carbó N, Fuster G (2024)
The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma
Breast Cancer Res, 26 (1), 122
DOI 10.1186/s13058-024-01871-0, PubMed 39138514

Nader K, Tasci M, Ianevski A, Erickson A, Verschuren EW, Aittokallio T, Miihkinen M (2024)
ScType enables fast and accurate cell type identification from spatial transcriptomics data
Bioinformatics, 40 (7)
DOI 10.1093/bioinformatics/btae426, PubMed 38936341

Nymoen HM, Alver TN, Horndalsveen H, Eide HA, Bjaanæs MM, Brustugun OT, Grønberg BH, Haakensen VD, Helland Å (2024)
Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial
Front Oncol, 14, 1412716
DOI 10.3389/fonc.2024.1412716, PubMed 39148905

Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499

Otterlei Fjørtoft M, Huse K, Rye IH (2024)
The Tumor Immune Microenvironment in Breast Cancer Progression
Acta Oncol, 63, 359-367
DOI 10.2340/1651-226X.2024.33008, PubMed 38779867

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncol, 63, 379-384
DOI 10.2340/1651-226X.2024.28322, PubMed 38779911

Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner L et al. (2024)
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma
Hemasphere, 8 (12), e70001
DOI 10.1002/hem3.70001, PubMed 39619245

Schulman A, Rousu J, Aittokallio T, Tanoli Z (2024)
Attention-based approach to predict drug-target interactions across seven target superfamilies
Bioinformatics, 40 (8)
DOI 10.1093/bioinformatics/btae496, PubMed 39115379

Shahrouzi P, Forouz F, Mathelier A, Kristensen VN, Duijf PHG (2024)
Copy number alterations: a catastrophic orchestration of the breast cancer genome
Trends Mol Med, 30 (8), 750-764
DOI 10.1016/j.molmed.2024.04.017, PubMed 38772764

Stålberg SM, Silwal-Pandit L, Bastani NE, Nebdal DJH, Lingjærde OC, Skålhegg BS, Kure EH (2024)
Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease
BMC Cancer, 24 (1), 555
DOI 10.1186/s12885-024-12320-8, PubMed 38702616

Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C et al. (2024)
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia
J Clin Invest, 134 (8)
DOI 10.1172/JCI168536, PubMed 38618957

Tafavvoghi M, Sildnes A, Rakaee M, Shvetsov N, Bongo LA, Busund LR, Møllersen K (2024)
Deep learning-based classification of breast cancer molecular subtypes from H&E whole-slide images
J Pathol Inform, 16, 100410
DOI 10.1016/j.jpi.2024.100410, PubMed 39720418

Tanoli Z, Schulman A, Aittokallio T (2024)
Validation guidelines for drug-target prediction methods
Expert Opin Drug Discov, 20 (1), 31-45
DOI 10.1080/17460441.2024.2430955, PubMed 39568436

Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H et al. (2024)
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
Acta Oncol, 63, 385-391
DOI 10.2340/1651-226X.2024.34791, PubMed 38779910

Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD (2024)
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
Eur J Nucl Med Mol Imaging, 52 (2), 693-707
DOI 10.1007/s00259-024-06853-0, PubMed 39133306

Tomasova K, Seborova K, Kroupa M, Horak J, Kavec M, Vodickova L, Rob L, Hruda M, Mrhalova M, Bartakova A, Bouda J, Fleischer T, Kristensen VN, Vodicka P, Vaclavikova R (2024)
Telomere length as a predictor of therapy response and survival in patients diagnosed with ovarian carcinoma
Heliyon, 10 (13), e33525
DOI 10.1016/j.heliyon.2024.e33525, PubMed 39050459

Ullern A, Holm K, Røssevold AH, Andresen NK, Bang C, Lingjærde OC, Naume B, Hov JR, Kyte JA (2024)
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13760, PubMed 39545921

van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D, Curigliano G, Czarnecka AM, Dienstmann R, Horak P, Italiano A, Marchiò C, Monkhorst K, Pritchard CC, Reardon B, Russnes HEG, Sirohi B, Sosinsky A, Spanic T, Turnbull C, Van Allen E, Westphalen CB, Tamborero D, Mateo J (2024)
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
Ann Oncol, 35 (11), 954-967
DOI 10.1016/j.annonc.2024.06.018, PubMed 39112111

von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, Müller TA, Pützer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanmäki H, Neubauer HA, Moriggl R, Mazzeo P, Schmidt N, Koch R, Hallek M, Chebel A, Armisen D et al. (2024)
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses
Blood, 144 (15), 1595-1610
DOI 10.1182/blood.2023022884, PubMed 38941598

Zhao Z, Zobolas J, Zucknick M, Aittokallio T (2024)
Tutorial on survival modeling with applications to omics data
Bioinformatics, 40 (3)
DOI 10.1093/bioinformatics/btae132, PubMed 38445722